Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria
Loren G. Fong,1*David Frost,2Margarita Meta,3Xin Qiao,1Shao H. Yang,1Catherine Coffinier,1Stephen G. Young1*
Progerias are rare genetic diseases characterized by prematureaging. Several progeroid disorders are caused by mutations thatlead to the accumulation of a lipid-modified (farnesylated)form of prelamin A, a protein that contributes to the structuralscaffolding for the cell nucleus. In progeria, the accumulationof farnesylprelamin A disrupts this scaffolding, leadingto misshapen nuclei. Previous studies have shown that farnesyltransferaseinhibitors (FTIs) reverse this cellular abnormality. We testedthe efficacy of an FTI (ABT-100) in Zmpste24-deficient mice,a mouse model of progeria. The FTI-treated mice exhibited improvedbody weight, grip strength, bone integrity, and percent survivalat 20 weeks of age. These results suggest that FTIs may havebeneficial effects in humans with progeria.
1 Department of Medicine/Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. 2 Abbott Laboratories, Abbott Park, IL 60064, USA. 3 Department of Radiology, University of California, San Francisco, CA 94107, USA.
* To whom correspondence should be addressed. E-mail: lfong{at}mednet.ucla.edu; sgyoung{at}mednet.ucla.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
NEWS OF THE WEEK
John Travis (17 February 2006) Science311 (5763), 934a.
[DOI: 10.1126/science.311.5763.934a] |Summary »|Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Epidermal expression of the truncated prelamin A causing Hutchinson-Gilford progeria syndrome: effects on keratinocytes, hair and skin.
Y. Wang, A. A. Panteleyev, D. M. Owens, K. Djabali, C. L. Stewart, and H. J. Worman (2008)
Hum. Mol. Genet.
17, 2357-2369
|Abstract »|Full Text »|PDF »
A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells.
C. Coffinier, S. E. Hudon, R. Lee, E. A. Farber, C. Nobumori, J. H. Miner, D. A. Andres, H. P. Spielmann, C. A. Hrycyna, L. G. Fong, et al. (2008)
J. Biol. Chem.
283, 9797-9804
|Abstract »|Full Text »|PDF »
Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin.
T. Dechat, K. Pfleghaar, K. Sengupta, T. Shimi, D. K. Shumaker, L. Solimando, and R. D. Goldman (2008)
Genes & Dev.
22, 832-853
|Abstract »|Full Text »|PDF »
Eliminating the Synthesis of Mature Lamin A Reduces Disease Phenotypes in Mice Carrying a Hutchinson-Gilford Progeria Syndrome Allele.
S. H. Yang, X. Qiao, E. Farber, S. Y. Chang, L. G. Fong, and S. G. Young (2008)
J. Biol. Chem.
283, 7094-7099
|Abstract »|Full Text »|PDF »
Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A.
Y. Liu, Y. Wang, A. E. Rusinol, M. S. Sinensky, J. Liu, S. M. Shell, and Y. Zou (2008)
FASEB J
22, 603-611
|Abstract »|Full Text »|PDF »
Disease Progression in Hutchinson-Gilford Progeria Syndrome: Impact on Growth and Development.
L. B. Gordon, K. M. McCarten, A. Giobbie-Hurder, J. T. Machan, S. E. Campbell, S. D. Berns, and M. W. Kieran (2007)
Pediatrics
120, 824-833
|Abstract »|Full Text »|PDF »
Farnesyl transferase inhibitor resistance probed by target mutagenesis.
T. Raz, V. Nardi, M. Azam, J. Cortes, and G. Q. Daley (2007)
Blood
110, 2102-2109
|Abstract »|Full Text »|PDF »
Mechanisms of Cardiovascular Disease in Accelerated Aging Syndromes.